Public Policy InitiativeACCP Trusted Source icon


ACCP has developed a Public Policy Initiative to ensure that its views are presented to the public and governmental leaders. This effort will be in concert with other organizations that are already working together to articulate a common viewpoint. A primary goal of the initiative will be to explain the importance of clinical pharmacology in the effort to encourage the optimal use of therapeutics to improve healthcare for all.

Starting in 2022, ACCP has chosen to designate each statement it issues as one of the following:

  • A Policy Statement can be a broad topic but should be something ACCP owns and can enforce and for which it is accountable (“this is ACCP’s policy”). It is anticipated that the Policy Statements will be fewer in number that the other categories.
  • A Position Paper is when we express our position on a specific issue, including when we are encouraging others to take action.
  • A Practice Paper encompasses clinical care by physicians and/or pharmacists and how they perform their professional responsibilities. It could encompass ethical issues and may be a recommendation of a change or refining a practice.

ACCP will issue Policy Statements, Position Papers and Practice Papers on topics concerning and relevant to clinical pharmacology, and seek to represent the views of the society on these topics through the following efforts:

  • Work with US Congress and key congressional committees to support annual funding for the US Food and Drug Administration, National Institutes of Health and the Agency for Healthcare Research and Quality;
  • Support additional funding for clinical pharmacology with a focus on the translation of biomedical and clinical research into healthcare and health, including comparative effectiveness research, by the Agency for Healthcare Research & Quality and the National Institutes of Health and other federal agencies as appropriate;
  • Collaborate with other scientific and educational organizations to develop Policy Statements on legislation impacting clinical pharmacology, drug development, the US Food and Drug Administration and National Institutes of Health, and articulate those positions to key legislators;
  • Seek opportunities to support clinical pharmacology issues and programs outside the US to further the science of the discipline, enhance the efficiency of drug development and encourage the optimal use of therapeutics to improve healthcare for all.

Select Archived Public Policy Statements